Immunotherapy efficacy between exon 19 deletion and exon 21 L858R mutation in advanced EGFR mutant non-small-cell lung cancer: a direct and indirect meta-analysis
For advanced EGFR mutant NSCLC patients, 21 L858R had superior IO efficacy compared with 19 Del.
Authors
- Zihong Chen (ORCID: https://orcid.org/0009-0001-9314-1683)
- Lanlan Pang (ORCID: https://orcid.org/0000-0002-4932-8117)
- Li Zhang (ORCID: https://orcid.org/0000-0001-7847-2452)
- Lin Zhang (ORCID: https://orcid.org/0000-0003-4241-4351)
- Yang Yuwen
- Jianhua Zhan
- Wenfeng Fang (ORCID: https://orcid.org/0000-0002-6440-8246)
- Yaxiong Zhang (ORCID: https://orcid.org/0000-0002-3632-0300)
- Kangqiao Xiong (ORCID: https://orcid.org/0009-0003-3284-7230)
- Xinyi He
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/tlcr-24-884
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52